

MINUTE
 AREA DRUG AND THERAPEUTICS COMMITTEE
 WEDNESDAY 17th AUGUST 2022 @10am
 Microsoft Teams Meeting

In Attendance:

Dr Mehrdad Malekian	Mrs Karen Patterson	Mrs Katrina Maroni
Mr George Lindsay	Mrs Carol McGoff	Dr Iain Hathorn
Mrs Emma Harris	Ms Ann Auld	Dr Stephanie Dundas
Dr David Semple	Mrs Christine Gilmour	Mr John Milne
Mrs Gail Richardson		
	Mrs Christine Gilmour	Mr John Milne

2022/126 1.	<p><u>Apologies for Absence</u></p> <p>Penny Brankin, Mr Angus, Dr Smyth, Mrs Johnstone</p>	
2022/127 2.	<p><u>Declaration of Interest</u></p> <p>There were no declarations of interest.</p>	
2022/128 3.	<p><u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 20th July 2022</u></p> <p>These were accepted as a true record and can now be published.</p> <p>b. <u>Steroid Emergency Cards</u></p> <p>Mrs Gilmour confirmed that Dr Burns is going to cascade guidance via the Chiefs of Medicine with an emphasis on appropriate specialities.</p> <p>Mrs Gilmour also confirmed that Mr Damien Corr will represent NHS Lanarkshire on a Scotland wide working group looking at how prescribing data can aid targeting of this card to appropriate patients.</p> <p>c. <u>A guideline for Periprocedure management of coagulation</u></p> <p>Dr Malekian confirmed that this was now complete and arrangements are being made for publication via the guidelines APP.</p>	

	<p>Mrs Richardson reported that Mrs Helen Barclay and Dr Hung are reviewing the Heparin Chart to make it consistent with this new guideline.</p> <p>d. <u>SC Omeprazole</u></p> <p>There was agreement that this guideline be approved subject to confirmation that the use outwith licence was in accordance with recognised national palliative care practice and that additional ULM processes would not be required. In addition some small typographical issues need be corrected.</p> <p>POST MEETING NOTE: Discussion between Mrs Richardson and Mrs Johnstone confirmed that this is recognised practice</p> <p>e. <u>SAPG outpatient parenteral antimicrobial therapy (OPAT) skin and soft tissue infection (SSTI) pathway</u></p> <p>Dr Dundas explained the background and the “Once for Scotland” approach being taken. She also explained that there was nothing controvesional in this information and in many ways it described current practice.</p>	
2022/129 4.	<p><u>SMC Advice</u></p> <p><u>Full Submissions</u></p> <p>Delta-9-tetrahydrocannabinol and cannabidiol (Sativex®) SMC2473 This was noted and will be referred to Neurology.</p> <p>Nivolumab (Opdivo®) SMC2458 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p>Velmanase alfa (Lamzede®) SMC2466 This was noted.</p> <p><u>Update on the interim assessment approach in response to COVID-19</u></p> <p>This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for one abbreviated submission noted below will be published on the SMC website on Monday 08 August 2022.</p>	

	<p><u>Full Submissions</u></p> <p>Tofacitinib (Xeljanz®) SMC2463</p> <p>This was noted and will be referred to Rheumatology.</p> <p>Apalutamide (Erleada®) SMC2472</p> <p>This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><u>Abbreviated Submission</u></p> <p>Estradiol /micronised progesterone (Bijuve®) SMC2502</p> <p>This was noted and will be referred to Gynaecology.</p> <p><u>Deferred Advice</u></p> <p>Imlifidase (Idefirix®) SMC2445</p> <p>This was noted.</p> <p>Trifarotene (Aklief®) SMC2441</p> <p>This was noted and will be referred to Dermatology.</p> <p>Zanubrutinib (Brukinsa®) SMC2452</p> <p>This was noted.</p> <p><u>Amended Advice</u></p> <p>Atezolizumab (Tecentriq®) SMC2492</p> <p>This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><u>Paediatric Licence Extensions</u></p> <p>These were noted.</p>	
2022/130 5.	<p><u>SMC follow up</u></p> <p>Mrs McGoff talked the Committee through the SMC follow up which had been previously circulated. Feedback and clinical protocols are expected on a number of items in due course.</p>	CMcG

2022/131 6.	<p><u>Lanarkshire Formulary</u></p> <p>Mrs McGoff brought back an additional amendment to the proposed naloxone nasal spray amendment from the previous meeting. This was the addition of naloxone 400mcg/1ml injection for use in clinical healthcare settings.</p> <p>The above amendments were ratified by the Committee.</p>	<p>CMc G KM</p>
2022/132 7.	<p><u>Clinical Protocols</u></p> <p>a. <u>Osteoporosis Guideline</u></p> <p>There was a good discussion with the following information/opinions shared:</p> <ul style="list-style-type: none"> • There is a current shortage of bisphosphonate medicines and while the expectation is that this will not be long term it has highlighted the concept of a “drug holiday”. There are controversies with this concept but there may be value in incorporating the NHS Lanarkshire view in the guideline. • The guideline should be reformatted in the new template • The flow chart is complex and should be reviewed to try and simplify • Local arrangements for long term follow up of patients should be explained • The sequencing of the information should be reviewed and • Links to websites should be checked to ensure they are the most current. <p>Dr Malekian will feedback to Dr Munro.</p> <p>b. <u>Arterial CDT thrombolysis clinical guidance for south west Scotland vascular network SSVN V1</u></p> <p>There are a number of issues including the need to ensure consistency between this guideline and others within NHS Lanarkshire e.g Management of Pulmonary Embolism.</p> <p>There is also a current shortage of alteplase and a requirement to direct it for nationally defined priority indications.</p> <p>Dr Malekian will feedback to Dr Ghibu.</p> <p>c. <u>CD Prescribing Protocol in OOH</u></p> <p>Dr Hathorn talked through this guideline which was approved. Dr Hathorn is arranging distribution within OOH and it will then be published via the guidelines APP.</p>	<p>MM</p> <p>MM</p>

2022/133 8.	<p><u>ADTC New Medicines Decisions</u></p> <p>This was noted.</p>	
2022/134 9.	<p><u>Unlicensed Medicines</u></p> <p>There was nil to report at today's meeting.</p>	
2022/135 10.	<p><u>Patient Group Directions</u></p> <p>There was nil to report at today's meeting.</p>	
2022/136 11.	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>This was noted.</p>	
2022/137 12.	<p><u>Regional Cancer Advisory Network</u></p> <p>There was nil to report at today's meeting.</p>	
2022/138 13.	<p><u>Patient Safety Alerts</u></p> <p>There was nil to report at today's meeting.</p>	
2022/139 14.	<p><u>Lay member related items</u></p> <p>Dr Malekian reported that Mr Bill Angus was stepping down from the ADTC after many years. He reported that he had sent thanks best wishes to Mr Angus for his sterling service and constructive contributions. This was echoed by all members.</p> <p>A replacement for Mr Angus will be sought</p>	
2022/140 15.	<p><u>ADTCC Correspondence</u></p> <p><u>(ADTC) Collaborative</u></p> <p>(i) MHRA Early Access to Medicines Scheme: Expiry of scheme for Avalglucosidase alfa 100mg powder for treatment of late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) EAMS 04425/0004</p> <p>This was noted.</p> <p>(ii) <u>ADTCC Forum</u></p> <p>Mr Lindsay reported that he had attended the ADTCC Forum last week. There were many topics discussed and a recurring theme was the acceleration of regional and "once for Scotland" working.</p>	

2022/141 16.	<p>Pharmacy & NMAHP Prescribing Governance</p> <p>There was nil to report at today's meeting.</p>	
2022/142 17.	<p><u>AOCB</u></p> <p>(i) <u>Screening of faecal transplant donors.</u></p> <p>Dr Dundas reported that she had received further information about international standards for the screening of faecal transplant donors and was very reassured that the supplies now agreed fulfil all recommendations.</p> <p>(ii) <u>Oral Iron</u></p> <p>Mrs Richardson talked about new recommendations for once daily oral iron administration to replace the traditional three times daily regimen. This would have implications for the formulary and HEPMA.</p> <p>The Committee will consider the issue, including any implementation and communications plan, at a future meeting.</p> <p>(iii) <u>Dr Hathorn's Retiral</u></p> <p>Dr Malekian thanked Dr Hathorn for his great service and very wise and experienced advice given at the ADTC and wider within NHS Lanarkshire. He also said that it had been a pleasure to work with Dr Hathorn for many years. All members wholeheartedly agreed.</p> <p>In reply Dr Hathorn explained how he had enjoyed the multidisciplinary working of the committee, contributing to its role in the governance of medicines within Lanarkshire and how he enjoyed the thoroughness of its work.</p> <p>Dr Malekian will seek advice from Dr Findlay about a replacement member for Dr Hathorn.</p> <p>(iv) <u>Meeting Dates 2023</u></p> <p>Meeting dates for 2023 were circulated.</p>	<p>GR</p> <p>MM</p>
2022/143 18.	<p><u>Date of next meeting</u></p> <p>Wednesday 21st September 2022 10am @ Microsoft Teams</p>	

--	--	--